LLY

770.02

+1.08%↑

JNJ

154.79

+0.6%↑

ABBV

189.86

+1.13%↑

NVO

74.91

+3.42%↑

UNH

303.63

+3.05%↑

LLY

770.02

+1.08%↑

JNJ

154.79

+0.6%↑

ABBV

189.86

+1.13%↑

NVO

74.91

+3.42%↑

UNH

303.63

+3.05%↑

LLY

770.02

+1.08%↑

JNJ

154.79

+0.6%↑

ABBV

189.86

+1.13%↑

NVO

74.91

+3.42%↑

UNH

303.63

+3.05%↑

LLY

770.02

+1.08%↑

JNJ

154.79

+0.6%↑

ABBV

189.86

+1.13%↑

NVO

74.91

+3.42%↑

UNH

303.63

+3.05%↑

LLY

770.02

+1.08%↑

JNJ

154.79

+0.6%↑

ABBV

189.86

+1.13%↑

NVO

74.91

+3.42%↑

UNH

303.63

+3.05%↑

Search

Cellectar Biosciences Inc

Avatud

0.35 -10.26

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.3

Max

0.39

Põhinäitajad

By Trading Economics

Töötajad

11

Turustatistika

By TradingEconomics

Turukapital

-845K

11M

Eelmine avamishind

10.61

Eelmine sulgemishind

0.35

Cellectar Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. dets 2024, 18:44 UTC

Suurimad hinnamuutused turgudel

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Võrdlus sarnastega

Hinnamuutus

Cellectar Biosciences Inc Prognoos

Hinnangu Konsensus

By TipRanks

Neutraalne

2 ratings

0

Osta

2

Hoia

0

Müü

Finantsandmed

$

Ettevõttest Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.